Loading
Life sciences · Journal article
The Professional Medical Journal · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: To compare the frequency of in hospital outcomes in patients of acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with intracoronary Tirofiban vs intravenous Tirofiban. Study Design: Non-randomized Controlled Trial. Setting: Department of Cardiology, Faisalabad Institute of Cardiology, Faisalabad. Period: Six months Nov 2025 to April 2026. Methods: Included 210 patients aged 20–65 years with STEMI undergoing primary PCI. Patients were equally divided into intracoronary (Group A) and intravenous (Group B) tirofiban groups. Outcomes assessed included Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow, TMP grade 2–3 flow, and MACE during hospital stay. Results: Intracoronary tirofiban resulted in significantly higher TIMI grade 3 flow (96.2% vs 80.0%, p<0.001) and TMP grade 2–3 flow (89.5% vs 67.6%, p<0.001) compared to intravenous administration. The incidence of MACE was significantly lower in the intracoronary group (11.4% vs 27.6%, p=0.003). Conclusion: Intracoronary administration of tirofiban was superior to intravenous administration route showing more improved coronary and myocardial perfusion and reduced in-hospital MACE in STEMI patients undergoing primary PCI.